Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) EPS (Basic) (2022 - 2026)

Lexeo Therapeutics' EPS (Basic) history spans 2 years, with the latest figure at $19.84 for Q4 2023.

  • On a quarterly basis, EPS (Basic) rose 323.93% to $19.84 in Q4 2023 year-over-year; TTM through Dec 2023 was -$12.4, a N/A change, with the full-year FY2025 number at -$1.86, up 39.81% from a year prior.
  • EPS (Basic) hit $19.84 in Q4 2023 for Lexeo Therapeutics, up from -$12.36 in the prior quarter.
  • Over the last five years, EPS (Basic) for LXEO hit a ceiling of $19.84 in Q4 2023 and a floor of -$12.36 in Q3 2023.